Completed PHASE3 INTERVENTIONAL 2-arm NCT00199927

Statins in Proteinuric Nephropathies (ESPLANADE)

A Prospective, Randomized, Multicenter Trial Testing the Antiproteinuric Effect of Statins Added to Combined ACE-inhibitor and Angiotensin Receptor Antagonist Therapy in Proteinuric, Chronic Nephropathies

Sponsor: Mario Negri Institute for Pharmacological Research

Conditions Chronic Nephropathy Hypertension Proteinuria

Interventions Fluvastatin standard therapy

Updated 6 times since 2017 Last updated: Apr 27, 2010 Started: Mar 31, 2003 Primary completion: Dec 31, 2007 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chronic Nephropathy and Hypertension, this trial is completed. The trial is conducted by Mario Negri Institute for Pharmacological Research and has accumulated 6 data snapshots since 2003. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mario Negri Institute for Pharmacological Research

Data source: Mario Negri Institute for Pharmacological Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Acireale, Italy , Bagno a Ripoli, Italy , Castelfranco Veneto, Italy , Catania, Italy , Catanzaro, Italy , Florence, Italy , Montevarchi, Italy , Padua, Italy , Palermo, Italy , Parma, Italy and 6 more locations